Lei Kai, Zhao Yutong, Li Shumin, Liu Jiawei, Chen Wenhao, Zhou Caihong, Zhang Yi, Tan Jinmei, Wu Jian, Zhou Qi, Tan Jiehui
Center of Hepato-Pancreato-Biliary Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Department of General Surgery, Hui Ya Hospital of The First Affiliated Hospital, Sun Yat-sen University, Huizhou, Guangdong, China.
Front Immunol. 2025 Jul 16;16:1589563. doi: 10.3389/fimmu.2025.1589563. eCollection 2025.
Programmed cell death (PCD) mechanisms play crucial roles in cancer progression and treatment response. This study aims to develop a PCD scores prediction model to evaluate the prognosis of hepatocellular carcinoma (HCC) and elucidate the tumor microenvironment differences.
We analyzed transcriptomic data from 363 HCC patients in the TCGA database and 221 patients in the GEO database to develop a PCD prediction model. Single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics sequencing (ST-seq) data from HCC patients were analyzed to investigate the tumor microenvironment and functional disparities. The oncogenic role of the key gene UBE2E1 in the model was explored in HCC through various experiments.
Seventeen PCD-related genes were identified as significant prognostic indicators, forming the basis of our PCD prediction model. High-PCD scores correlated with poorer overall survival (OS) and exhibited significant predictive capabilities. scRNA-seq analysis revealed distinct tumor cell characteristics and immune microenvironment differences between high- and low-PCD groups. High-PCD tumors showed increased cell proliferation and malignancy-associated gene expression. T cells in high-PCD patients were more likely to be exhausted, with elevated expression of exhaustion markers. ST-seq data also confirmed these results. Among the genes associated with the PCD prognostic model, UBE2E1 was identified as a key oncogenic marker in HCC.
The PCD prediction model effectively predicts prognosis in HCC patients and reveals critical insights into the tumor microenvironment and immune cell exhaustion. This study underscores the potential of PCD-related biomarkers in guiding personalized treatment strategies for HCC.
程序性细胞死亡(PCD)机制在癌症进展和治疗反应中起着关键作用。本研究旨在建立一个PCD评分预测模型,以评估肝细胞癌(HCC)的预后,并阐明肿瘤微环境差异。
我们分析了来自TCGA数据库的363例HCC患者和GEO数据库的221例患者的转录组数据,以建立PCD预测模型。分析了HCC患者的单细胞RNA测序(scRNA-seq)和空间转录组测序(ST-seq)数据,以研究肿瘤微环境和功能差异。通过各种实验探讨了模型中关键基因UBE2E1在HCC中的致癌作用。
鉴定出17个与PCD相关的基因作为显著的预后指标,构成了我们PCD预测模型的基础。高PCD评分与较差的总生存期(OS)相关,并具有显著的预测能力。scRNA-seq分析揭示了高PCD组和低PCD组之间不同的肿瘤细胞特征和免疫微环境差异。高PCD肿瘤显示细胞增殖增加和恶性相关基因表达增加。高PCD患者的T细胞更容易耗竭,耗竭标志物表达升高。ST-seq数据也证实了这些结果。在与PCD预后模型相关的基因中,UBE2E1被鉴定为HCC中的关键致癌标志物。
PCD预测模型有效地预测了HCC患者的预后,并揭示了对肿瘤微环境和免疫细胞耗竭的关键见解。本研究强调了PCD相关生物标志物在指导HCC个性化治疗策略方面的潜力。